PHARMA R&D

Drug Discovery and Repurposing for monogenic disorders

repurposing

Drug repurposing allows a reconciliation of the time of research with the one of medicine in order to meet the high medical need of genetic disorders

individualized drug discovery

Individualized screening of thousand molecules helps in identifying drug candidates for the patient ans potential new therapeutic targets.

development

The development of approved molecule is facilitated by the available knowledge produced by the former developments.

PATIENT ORGANIZATIONS
APTEEUS offers individualized research programs tailored to patients with rare monogenic diseases.
investors
APTEEUS wishes to develop its activity and to engage its first drug candidate into a pharmaceutical and clinical development.
partnership
APTEEUS has unique technology and know-how for drug discovery on primary cells.
Slider

APTEEUS is a biotech expert in drug discovery and repositioning in the field of rare monogenic diseases. We are particularly interested in pathologies whose medical need is significant and largely unmet. Our technology allows us to conduct individualized research projects in a few months and identify new drug candidates among all molecules already used in humans, in collaboration with patient organizations, physicians and academic and industrial partners. Our innovative activity, which is at odds with the traditional drug discovery approach, aims to achieve a rapid and significant social impact.

OUR TΞCHNOLOGY

Operando®

OPERANDO is the biomedical research program in place for collecting cutaneous biopsies from patients in order to isolate the cells “model” of the pathology.

evidenceFactory®

evidenceFactory is the processes we use to measure, in vitro, the causal defects of the symptoms. Based on cell imaging and mass spectrometry, they are systematically miniaturized and automated to quickly test several thousand molecules.

TEE Library®

TEE Library is our proprietary collection of molecules approved for human use and enriched daily that we test in every new screen.

NΞWs

We are not patients, we are not families, we are not doctors…but we live with…

Read more

APTEEUS has been awarded at the France Tech Transfer Invest 2019. France Tech Transfer Invest…

Read more

Apteeus has started a tailor-made research program for the association Les Petits Mec P2. Less…

Read more

LEADΞRSHIP

Dr. Terence Beghyn

Pharm.D & PhD in Medicinal Chemistry

Terence co-founded Apteeus after a career as an assistant Professor at the University of Lille. Passionate about drug discovery technologies, he now puts his expertise at the service of patients with orphan diseases. Terence is President of Apteeus.

Professor Benoit DEPREZ

Professor of Pharmacy

Benoit began his career in two biotech companies by leading the chemistry and drug discovery teams. Returning to the University in 2006, he set up a drug discovery laboratory at the Institut Pasteur de Lille, which was labelled by INSERM. Benoit is Scientific Director of the Institut Pasteur de Lille. He co-founded Apteeus and is strategic advisor.

partners